ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Choroidal vascularity and thickness modulation with topical nepafenac after phacoemulsification: a comparative study in diabetic and non-diabetic eyes.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effects of topical 0.3% nepafenac on choroidal thickness (CT), and the choroidal vascularity index (CVI) in diabetic and non-diabetic patients following uncomplicated phacoemulsification.
methodsThis prospective, randomized study included 104 eyes of 104 patients undergoing uneventful cataract surgery. Participants were randomized to receive topical nepafenac (Group 1, n = 54) or no nepafenac (Group 2, n = 50) and were further stratified by diabetic status (Groups 1A, 1B, 2A, 2B). Optical coherence tomography (OCT) and Enhanced Depth Imaging-OCT assessments of central macular thickness (CMT), CT, and CVI were conducted preoperatively, at postoperative week 1, and week 6. Nepafenac was administered once daily for 6 weeks in Group 1. Intergroup and intragroup changes were analyzed using appropriate statistical tests.
resultsAt postoperative week 6, CVI was significantly lower in the nepafenac group compared with controls (p = 0.015), while CMT and CT showed no significant between-group differences. In diabetic participants, CVI increases at week 1 and week 6 were significantly attenuated with nepafenac treatment (p = 0.015 and p = 0.021, respectively). Non-diabetic participants demonstrated no significant nepafenac-related changes in CMT, CT, or CVI (p > 0.05). CT increased during early postoperative follow-up in all groups, whereas no participant developed diabetic macular edema.
conclusionsTopical nepafenac significantly reduces postoperative increases in CVI-particularly in diabetic patients-suggesting a protective effect against inflammation-associated choroidal vascular alterations. Nepafenac may help preserve choroidal vascular integrity after cataract surgery, highlighting its value as an adjunctive anti-inflammatory therapy, especially for diabetic individuals at higher inflammatory risk.
Indexed as
Identifiers
42530590What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.